在胰腺不充分囊性纤维化中维护β细胞功能,使用高效的CFTR调节器治疗

Anneliese J Flatt1, Saba Sheikh2, Amy J Peleckis1

  • 1Division of Endocrinology, Diabetes & Metabolism, Department of Medicine and Institute for Diabetes, Obesity & Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.

概括

在囊性纤维化患者中,elexacaftor/tezacaftor/ivacaftor (ETI) 能够保持胰腺β细胞的功能. 与未经治疗的对照组不同,ETI改善了胰岛素分泌和亲胰岛素处理.